Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Asper Biotech, BioData


Illumina has begun selling a third generation of its mutation-linkage panel, a genome-wide set of SNP markers and validated assays. The panel is available either as part of a fast-track SNP-genotyping service or as a standard product for research centers already armed with a BeadArray genotyping instrument, Illumina said.

The Linkage Panell III, which can interrogate more than 4,600 SNP loci across the genome, is “ideally suited” for family-based genetic linkage studies.

Illumina’s BeadArray technology and GoldenGate assay protocol enable 96-well, plate-based sample handling and parallel analysis of more than 1,200 SNP markers per well, and nearly 120,000 genotypes per plate.

Estonian SNP-genotyping company Asper Biotech and BioData, an informatics shop, have jointly launched SNP Assistant for SNP management, validation, and analysis.

The technology, which is not platform dependent, enables researchers to perform marker and sample preparation; case control and TDT tests; ID calculation; relationship tests; and database comparisons, the companies said.

Filed under

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.